NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines

Clinical Pharmacology: Advances and Applications

Volumn 7, Issue , 2015, Pages 111-117

  North, William G ^a   Liu, Fuli ^a   Tian, Ruiyang ^a   Abbasi, Hamza ^a   Akerman, Bonnie ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Antibodies; Inhibitors; NMDA receptors; Ovarian cancer; Potential therapy

Indexed keywords

ANTIBODY; DIZOCILPINE MALEATE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POLYCLONAL ANTIBODY;

A2008 CELL LINE; A2780 CELL LINE; ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CELL VIABILITY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID ADENOCARCINOMA; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY ADENOCARCINOMA; OVARY CANCER; PROTEIN EXPRESSION; SKOV3 CELL LINE; STAINING; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84945948077     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S90367     Document Type: Article

References (25)

1. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A. 1995;92:7162-7166.
2. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol. 1989;166:591-592.
3. Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA. Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. J Neural Transm. 2011;2118:1255-1259.
4. Berman FW, Murray TF. Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity. J Biochem Toxicol. 1996;11:217-226.
5. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 1991;354:31-37.
6. Ishii T, Moriyoshi K, Sugihara H, et al. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem. 1993;268:2836-2843.
7. North WG, Gao G, Memoli VA, Pang RH, Lynch L. Breast cancer expresses functional NMDA receptors. Breast Cancer Res Treat. 2010;122:307-314.
8. North WG, Gao G, Jensen A, Memoli V, Du J. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. Clin Pharmacol. 2010;2:31-40.
9. Tuzin E, Zhou L, Baehring JM, Bannikh S, Resenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118: 737-743.
10. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
11. Will A, Akalin M. Paraneoplastic limbic encephalitis with NMDA receptor (NR1) antibodies in breast cancer. Neurology. 2012;78:S08.007.
12. Tachibana N, Shirakawa T, Ishii K, et al. Expression of various glutamate receptors including N-methyl-D-aspartate receptor (NMDAR) in ovarian teratoma removed from a young woman with anti-NMDAR encephalitis. Intern Med. 2010;49:2167-2173.
13. Tachibana N, Ikeda S. Localization of NMDAR-related epitopes in ovarian teratoma: comparison between patients and controls. Rinsho Shinkeigaku. 2012;52:982-984.
14. During MJ, Symes CW, Lawlor PA, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science. 2000;287:1453-1460.
15. Kawai Y, Hirakawa T, Sugisawa A, Motomura I. Acute and subacute toxicity studies of ifenprodil. Oyo Yakuri Pharmacometrics. 1975;10:785
16. Shalaby IA, Chenard BL, Prochniak MA, Butler TW. Neuroprotective effects of the N-methyl-D-aspartate receptor antagonists ifenprodil and SL-82.0715 on hippocampal cells in culture. J Pharmacol Exp Ther. 1992;260:925-932.
17. Graham D, Darles G, Langer SZ. The neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell culture toxicity studies. Eur J Pharmacol. 1992;226:373-376.
18. Mishra V, Verma R, Singh N, Raghubir R. The neuroprotective effects of NMDAR antagonist, ifenprodil and ASIC1a inhibitor, flurbiprofen on post-ischemic cerebral injury. Brain Res. 2011;1389:152-160.
19. Zhang W, Shi CX, Gu XP, Ma ZL, Zhu W. Antinociception and decreased the expression of NR2B subunits in the dorsal horn after chronic dorsal root ganglia compression in rats. Anesth Analg. 2009;108: 1015-1020.
20. Reynolds IJ, Miller RJ. Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Mol Pharmacol. 1989;36:758-765.
21. Williams K. Ifenprodil discriminates subtypes of N-methyl-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993;44:851-859.
22. Gallagher MJ, Huang H, Pritchett DB, Lynch DR. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 1996;271:9603-9611.
23. Bernardi M, Bertolini A, Szczawinska K, Genedani S. Blockage of polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine in mice. Eur J Pharmacol. 1996;298: 51-55.
24. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics focus on the NR2B subtype. Trends Pharmacol Sci. 2001;22:636-642.
25. Patent Abstracts of Japan Vol 10 no.377 (c-392) 16 December, 1986; and JP-A-61 72820(Grelan Pharmaceutical Co, Ltd), 4 December, 1986.